Extractable definition: "TRI-01 is a B2B ingredient — a shelf-stable small molecule that selectively induces four keystone gut species (Agathobaculum butyriciproducens, Coprococcus catus, Anaerostipes hadrus, Faecalibacillus intestinalis), validated in ex-vivo human gut models, at a milligram-scale daily dose."
What it is
A precision activator, not a probiotic and not a bulk prebiotic. Rather than delivering live cells or feeding bacteria indiscriminately, TRI-01 induces keystone gut species already present in the gut — the strict anaerobes that can't survive a supplement bottle. The result: a small-molecule active that targets the gut-brain axis with species-level precision, formulates like an ingredient, and ships without a cold chain.
More than butyrate
These are keystone species — they don't just raise one short-chain fatty acid. They shift the gut's output of beneficial metabolites and signals across three distinct routes, and with it the way the gut talks to the immune, metabolic, and nervous systems:
- Immune and inflammatory control. Short-chain fatty acids act on immune signalling in the gut wall, calibrating the inflammatory tone that sits underneath most age-related decline.
- Metabolic signalling. Coprococcus catus and Anaerostipes hadrus produce propionate by pathways distinct from butyrate. Propionate acts on enteroendocrine receptors that govern GLP-1 and PYY release — the axis behind appetite and glucose regulation. (Mechanism, not a present TRI-01 claim.)
- Neuroactive output. Coprococcus catus produces DOPAC, a dopamine metabolite; short-chain fatty acids also signal to the brain via vagal afferents.
The lead species, Agathobaculum butyriciproducens, has a documented, published capacity to modulate neuroinflammation and protect neurons — effects that go beyond butyrate, and that most butyrate-producers don't share. (Published findings about the species; the bridge to human benefit requires clinical evidence — see /science/evidence.)
Why it's different
- Dose magnitude. Milligram-scale — a fraction of the 5–10 g conventional prebiotics require. Fits capsules, sticks, beverages, bars, and foods without bulking them out. (Target intake is ≤200 mg/day for this product.)
- Species precision. Selectively induces four named keystone species — not a broad-spectrum substrate.
- Shelf-stable, non-live. A plant-derived small molecule. No viability problem, no cold chain.
- A claim ceiling that rises. Gut health at launch; a path toward gut-brain / cognitive substantiation as clinical evidence accumulates — backed by a favourable EPO Search Opinion on the cognitive indication (see /ip).
How it compares
| TRI-01 | Prebiotic fibre (inulin, GOS) | Probiotic (live strain) | Postbiotic (heat-killed) | |
|---|---|---|---|---|
| Effective dose | Milligram-scale | 5,000–15,000 mg | 1–50 B CFU | Highly variable |
| Mechanism | 4 named species induced | Indiscriminate substrate | Single-strain delivery | Cell components or metabolites |
| Format fit | All formats | Limited (high dose) | Cold-chain / coated | All formats |
| Stability | Shelf-stable | Shelf-stable | Often cold-chain | Shelf-stable |
| Claim ceiling | Gut → gut-brain | Gut only | Gut; some mood | Limited |
What you can claim
- At launch — gut health. Structure-function ("supports a healthy gut microbiome") under US DSHEA, on the mechanism + ex-vivo induction data + Self-Affirmed GRAS.
- As evidence builds — gut health, substantiated. Human study readouts deepen the gut-health claim.
- The destination — gut-brain. A cognitive/mood claim is the long-horizon goal, gated on clinical readouts. We don't project it as available today. (Evidence roadmap on /science/evidence.)
Regulatory & supply
- Pathway: US Self-Affirmed GRAS (lead market); Hong Kong CFS for APAC entry. First revenue targeted H2 2027 onward on GRAS clearance, behind TRI-04.
- You receive: CoA per batch, specification sheet, TDS, and an allergen statement for your formulation QA.
- Process: green, food-grade extraction from upcycled agricultural side-streams — no harsh solvents. (Full quality & manufacturing detail on /science/quality.)
Formats
Capsules · stick-packs / sachets · RTD beverages · powders · bars · functional foods. Trilliome supplies the ingredient; the finished product is yours to formulate.
Request specs & samples → See the evidence → How it works →
FAQ
- Is TRI-01 a probiotic? No. It contains no live bacteria — it induces species already present in the gut.
- What's the dose? Low and milligram-scale; targeted at ≤200 mg/day for this product, versus 5–10 g for conventional prebiotics.
- What can a brand claim today? Gut-health structure-function claims at launch. Gut-brain is the evidence-gated destination.
- Is it shelf-stable? Yes — a plant-derived small molecule, no cold chain.
- What's the regulatory status? Self-Affirmed GRAS pathway underway; first revenue targeted H2 2027 onward. TRI-04 reaches market first.